The extension suggests closing conditions are not yet fully satisfied. Monitor for a closing announcement by October 16, 2026 — failure to close by that date would reintroduce capital structure uncertainty for this clinical-stage biotech.
Price Chart
Executive Summary
Indaptus Therapeutics extended the outside closing date for its previously announced $24.0 million private placement from September 29, 2026 to October 16, 2026, and permitted a deferred coordinated closing. The filing is a routine administrative extension of the stock purchase agreement's closing timeline, with no changes to the economic terms or the aggregate gross proceeds.
Key Facts
- The outside closing date for the $24.0 million private placement was extended from September 29, 2026 to October 16, 2026.
- The extension allows the company to defer and coordinate the closing until conditions are satisfied or waived, but no later than the new outside date.
- The deadline for purchasers to fund their subscription amounts and certain termination rights were also extended to October 16, 2026.
- All other terms of the original Stock Purchase Agreement remain unchanged and in full force.
Financial Impact
No change to the previously announced $24.0 million gross proceeds; the extension is procedural and does not alter the deal's economics.
Risk Factors
- If the private placement fails to close by October 16, 2026, the company may face a near-term cash shortfall.
- The deferred closing structure introduces execution risk; any purchaser backing out could reduce the total proceeds.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045040 |
| Exhibit: ex10-1.htm | 0001493152-26-045040 |
| Document: 0001493152-26-045040-index-headers.html | 0001493152-26-045040 |
| Document: 0001493152-26-045040-index.html | 0001493152-26-045040 |
| Document: 0001493152-26-045040.txt | 0001493152-26-045040 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.39 (+7.39%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.39 (+7.39%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.39 (+7.39%) |
Oct 21, 2026 5d ago | SC 13D/A | $2.99 | awaiting T+60 | — | $3.39 (+13.49%) |
Oct 20, 2026 6d ago | 8-K | $3.16 | awaiting T+60 | — | $3.39 (−7.39%) |
Sep 30, 2026 27d ago | 8-K | $2.30 | awaiting T+60 | — | $3.39 (+47.54%) |
Sep 9, 2026 6w ago | 8-K | $2.56 | awaiting T+60 | — | $3.39 (−32.56%) |
Sep 4, 2026 7w ago | 424B5 | $1.85 | awaiting T+60 | — | $3.39 (−83.43%) |
Sep 1, 2026 8w ago | 8-K | $1.13 | awaiting T+60 | — | $3.39 (−200.31%) |
Aug 26, 2026 8w ago | EFFECT | $1.14 | awaiting T+60 | — | $3.39 (−197.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers